Compare Five9 Inc (FIVN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs 10X Genomics Inc — how do they compare? Five9 Inc trades at $31.07 (market cap $2.44B), while 10X Genomics Inc trades at $57.12 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 3.1× Five9 Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| FIVN | TXG | |
|---|---|---|
Market Cap | $2.44B | $7.61B |
Sector | Technology | Health |
52-Week High | $34.48 | $58.57 |
52-Week Low | $13.61 | $11.34 |
Enterprise Value | $2.59B | $7.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIVN trades at $31.37, down 9.02% in the past day but remains near its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million. Recent management appointments and AI-driven subscription growth provide operational tailwinds.
Outlook is positive given earnings beats and analyst consensus, but risks include high valuation multiples and negative cash flow trends. The stock offers growth potential but requires monitoring of debt levels and competitive pressures in the CX software space.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
